Details
Stereochemistry | RACEMIC |
Molecular Formula | C11H13N3O |
Molecular Weight | 203.2404 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=NC(C)=CC=C1CN2CC2C#N
InChI
InChIKey=KOYMTVWMCXDJNV-UHFFFAOYSA-N
InChI=1S/C11H13N3O/c1-8-3-4-9(11(13-8)15-2)6-14-7-10(14)5-12/h3-4,10H,6-7H2,1-2H3
Molecular Formula | C11H13N3O |
Molecular Weight | 203.2404 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Ciamexon is an aziridine derivative with potent immuno-modulating activity developed by German pharmaceutical company Boehringer Mannheim G.m.b.H. for autoimmune diseases treatment. Ciamexon shows promising effects in experimental models of rheumatoid arthritis, diabetes, and obesity without toxic side effects. In animal studies, Ciamexon inhibits the proliferation of autoreactive lymphocytes dose-dependently, without affecting the reaction against foreign antigens. Clinical efficacy evaluation of the Ciamexon in patients with rheumatoid arthritis shows significant, dose-dependent improvement in both the clinical and the biochemical disease activity indexes. The major adverse effects of Ciamexon were hepatotoxicity, diarrhea, and rash.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2189417
400 mg/day of ciamexon for 6 mounths
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:32:54 GMT 2023
by
admin
on
Fri Dec 15 16:32:54 GMT 2023
|
Record UNII |
325PG708LF
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C308
Created by
admin on Fri Dec 15 16:32:54 GMT 2023 , Edited by admin on Fri Dec 15 16:32:54 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000081899
Created by
admin on Fri Dec 15 16:32:54 GMT 2023 , Edited by admin on Fri Dec 15 16:32:54 GMT 2023
|
PRIMARY | |||
|
C76067
Created by
admin on Fri Dec 15 16:32:54 GMT 2023 , Edited by admin on Fri Dec 15 16:32:54 GMT 2023
|
PRIMARY | |||
|
5588
Created by
admin on Fri Dec 15 16:32:54 GMT 2023 , Edited by admin on Fri Dec 15 16:32:54 GMT 2023
|
PRIMARY | |||
|
71759
Created by
admin on Fri Dec 15 16:32:54 GMT 2023 , Edited by admin on Fri Dec 15 16:32:54 GMT 2023
|
PRIMARY | |||
|
75985-31-8
Created by
admin on Fri Dec 15 16:32:54 GMT 2023 , Edited by admin on Fri Dec 15 16:32:54 GMT 2023
|
PRIMARY | |||
|
325PG708LF
Created by
admin on Fri Dec 15 16:32:54 GMT 2023 , Edited by admin on Fri Dec 15 16:32:54 GMT 2023
|
PRIMARY | |||
|
C035520
Created by
admin on Fri Dec 15 16:32:54 GMT 2023 , Edited by admin on Fri Dec 15 16:32:54 GMT 2023
|
PRIMARY | |||
|
SUB06224MIG
Created by
admin on Fri Dec 15 16:32:54 GMT 2023 , Edited by admin on Fri Dec 15 16:32:54 GMT 2023
|
PRIMARY | |||
|
CHEMBL2104100
Created by
admin on Fri Dec 15 16:32:54 GMT 2023 , Edited by admin on Fri Dec 15 16:32:54 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |